The evolving role of glycoprotein IIb/IIIa inhibitor therapy in contemporary care of acute coronary syndrome patients

Pierluigi Tricoci, Eric D. Peterson

Research output: Contribution to journalReview articlepeer-review

Abstract

Results from clinical trials of glycoprotein IIb/IIIa(GPIIb/IIIa) inhibitors during the past decade have established their current role in the treatment of non-ST -segment elevation acute coronary syndrome and in percutaneous coronary interventions. However, there are still unanswered questions on optimal use of GPIIb/IIIa inhibitors. Moreover, as new concomitant or alternative medications become available, the role of GPIIb/IIIa inhibitors must be reconsidered. This review discusses, in the light of clinical trials recently presented, what we know, what we are learning, and what we still need to learn.

Original languageEnglish (US)
Pages (from-to)449-455
Number of pages7
JournalJournal of Interventional Cardiology
Volume19
Issue number5
DOIs
StatePublished - Oct 2006
Externally publishedYes

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'The evolving role of glycoprotein IIb/IIIa inhibitor therapy in contemporary care of acute coronary syndrome patients'. Together they form a unique fingerprint.

Cite this